Display options
Cite
Shatizadeh Malekshahi S, Arefian E, Salimi V, et al. Potential siRNA Molecules for Nucleoprotein and M2/L Overlapping Region of Respiratory Syncytial Virus: In Silico Design. Jundishapur J Microbiol. 2016;9(4):e34304doi: 10.5812/jjm.34304.
Shatizadeh Malekshahi, S., Arefian, E., Salimi, V., Mokhtari Azad, T., & Yavarian, J. (2016). Potential siRNA Molecules for Nucleoprotein and M2/L Overlapping Region of Respiratory Syncytial Virus: In Silico Design. Jundishapur journal of microbiology, 9(4), e34304. https://doi.org/10.5812/jjm.34304
Shatizadeh Malekshahi, Somayeh, et al. "Potential siRNA Molecules for Nucleoprotein and M2/L Overlapping Region of Respiratory Syncytial Virus: In Silico Design." Jundishapur journal of microbiology vol. 9,4 (2016): e34304. doi: https://doi.org/10.5812/jjm.34304
Shatizadeh Malekshahi S, Arefian E, Salimi V, Mokhtari Azad T, Yavarian J. Potential siRNA Molecules for Nucleoprotein and M2/L Overlapping Region of Respiratory Syncytial Virus: In Silico Design. Jundishapur J Microbiol. 2016 Apr 23;9(4):e34304. doi: 10.5812/jjm.34304. eCollection 2016 Apr. PMID: 27303618; PMCID: PMC4902852.
Copy Download .nbib Format: NLM
Share it on

Jundishapur J Microbiol. 2016 Apr 23;9(4):e34304. doi: 10.5812/jjm.34304. eCollection 2016 Apr.

Potential siRNA Molecules for Nucleoprotein and M2/L Overlapping Region of Respiratory Syncytial Virus: In Silico Design.

Jundishapur journal of microbiology

Somayeh Shatizadeh Malekshahi, Ehsan Arefian, Vahid Salimi, Talat Mokhtari Azad, Jila Yavarian

Affiliations

  1. Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran.
  2. Department of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, IR Iran.

PMID: 27303618 PMCID: PMC4902852 DOI: 10.5812/jjm.34304

Abstract

BACKGROUND: Human respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease in the pediatric population, elderly and in immunosuppressed individuals. Respiratory syncytial virus is also responsible for bronchiolitis, pneumonia, and chronic obstructive pulmonary infections in all age groups. With this high disease burden and the lack of an effective RSV treatment and vaccine, there is a clear need for discovery and development of novel, effective and safe drugs to prevent and treat RSV disease. The most innovative approach is the use of small interfering RNAs (siRNAs) which represent a revolutionary new concept in human therapeutics. The nucleoprotein gene of RSV which is known as the most conserved gene and the M2/L mRNA, which encompass sixty-eight overlapping nucleotides, were selected as suitable targets for siRNA design.

OBJECTIVES: The present study is aimed to design potential siRNAs for silencing nucleoprotein and an overlapping region of M2-L coding mRNAs by computational analysis.

MATERIALS AND METHODS: Various computational methods (target alignment, similarity search, secondary structure prediction, and RNA interaction calculation) have been used for siRNA designing against different strains of RSV.

RESULTS: In this study, seven siRNA molecules were rationally designed against the nucleoprotein gene and validated using various computational methods for silencing different strains of RSV. Additionally, three effective siRNA molecules targeting the overlapping region of M2/L mRNA were designed.

CONCLUSIONS: This approach provides insight and a validated strategy for chemical synthesis of an antiviral RNA molecule which meets many sequence features for efficient silencing and treatment at the genomic level.

Keywords: In Silico; RSV; siRNA

References

  1. Antiviral Res. 2015 Mar;115:71-4 - PubMed
  2. Nat Rev Genet. 2007 Mar;8(3):173-84 - PubMed
  3. Antisense Nucleic Acid Drug Dev. 1998 Dec;8(6):507-16 - PubMed
  4. J Virol. 1999 Jan;73(1):170-6 - PubMed
  5. RNA. 2006 Jul;12(7):1179-87 - PubMed
  6. J Gen Virol. 2006 Jul;87(Pt 7):1805-21 - PubMed
  7. Early Hum Dev. 2009 Oct;85(10 Suppl):S31-5 - PubMed
  8. Biochem Biophys Res Commun. 2004 Apr 16;316(4):1050-8 - PubMed
  9. Mol Ther. 2012 Mar;20(3):513-24 - PubMed
  10. Cell. 2007 Jul 13;130(1):101-12 - PubMed
  11. J Virol. 2001 Jul;75(14):6566-71 - PubMed
  12. PLoS One. 2014 Mar 13;9(3):e90786 - PubMed
  13. Antivir Ther. 2012;17(1 Pt B):213-25 - PubMed
  14. RNA. 2005 Jun;11(6):864-72 - PubMed
  15. Paediatr Respir Rev. 2009 Jun;10 Suppl 1:23-5 - PubMed
  16. Nature. 2001 May 24;411(6836):494-8 - PubMed
  17. J Virol. 2009 Jul;83(13):6326-34 - PubMed
  18. Nat Biotechnol. 2004 Mar;22(3):326-30 - PubMed
  19. Front Bioeng Biotechnol. 2014 Dec 11;2:65 - PubMed
  20. Nat Methods. 2006 Mar;3(3):199-204 - PubMed
  21. Nucleic Acids Res. 2004 Feb 09;32(3):936-48 - PubMed
  22. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):81-5 - PubMed
  23. Nucleic Acids Res. 2004 Aug 27;32(15):4609-17 - PubMed
  24. Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W130-4 - PubMed
  25. Clin Infect Dis. 2010 May 1;50(9):1258-67 - PubMed
  26. Clin Sci (Lond). 2006 Jan;110(1):47-58 - PubMed
  27. Mol Med Rep. 2012 Jul;6(1):9-15 - PubMed
  28. Bioinformation. 2011;6(9):340-3 - PubMed
  29. Drug Discov Today. 2009 Sep;14(17-18):851-8 - PubMed
  30. N Biotechnol. 2013 Jan 25;30(2):159-65 - PubMed
  31. Retrovirology. 2007 Nov 08;4:80 - PubMed
  32. Infect Genet Evol. 2014 Mar;22:130-3 - PubMed
  33. Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1892-7 - PubMed
  34. Nat Biotechnol. 2003 Jun;21(6):635-7 - PubMed
  35. Bioinformation. 2012;8(11):519-22 - PubMed
  36. Algorithms Mol Biol. 2006 Mar 16;1(1):3 - PubMed
  37. Virology. 1997 Sep 15;236(1):188-201 - PubMed
  38. Pediatr Infect Dis J. 2010 Oct;29(10):931-3 - PubMed
  39. Clin Rev Allergy Immunol. 2013 Dec;45(3):331-79 - PubMed
  40. Virus Res. 2014 Aug 30;189:293-302 - PubMed
  41. Crit Care Med. 2013 Jan;41(1):205-14 - PubMed

Publication Types